Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 21, 2017

Galapagos reports Phase II data of cystic fibrosis drug

Belgium-based biotechnology firm Galapagos has reported positive topline data from the Phase II ALBATROSS clinical trial of GLPG2222 in patients with heterozygous class III/F508del cystic fibrosis transmembrane conductance regulator (CFTR).

Belgium-based biotechnology firm Galapagos has reported positive topline data from the Phase II ALBATROSS clinical trial of GLPG2222 in patients with heterozygous class III/F508del cystic fibrosis transmembrane conductance regulator (CFTR).

GLPG2222 is an investigational C1 corrector that was administered on top of 150mg twice-daily ivacaftor (Kalydeco).

The investigational candidate was found to be well-tolerated, with mild or moderate treatment-emergent adverse events and no serious adverse events.

A dose-dependent increase in FEV1 and a statistically significant dose-dependent decrease in sweat chloride were observed during the trial.

Galapagos CSO Dr Piet Wigerinck said: “The ALBATROSS results are the first results demonstrating that GLPG2222 is well tolerated in CF patients.

“The ALBATROSS results are the first results demonstrating that GLPG2222 is well tolerated in CF patients.”

“In addition, the exposures achieved, coupled with the activity observed, support our dose selection plans for the investigational triple combination therapy.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“We are impressed with the magnitude of the effects we saw on sweat chloride and FEV1 in patients whose treatment with ivacaftor has been optimised following years of therapy.”

The randomised, double-blinded, placebo-controlled Phase II trial assessed the safety, tolerability and pharmacokinetics of once-a-day 150mg and 300mg doses of GLPG2222 in 37 subjects across Europe and Australia.

Throughout the trial, patients were given long-term stable Kalydeco treatment, and achieved targeted exposures of GLPG2222 consistent with those observed in healthy participants.

ALBATROSS principal investigator professor Scott Bell said: “The results of this trial are encouraging as they show that the addition of the novel CFTR corrector molecule GLPG2222 on top of highly efficacious CFTR modulator treatment already given for years in patients with gating mutations was well tolerated and may bring additional benefit to patients.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU